You are here: Industry Insights > drug

News List

Roche's drug scores expanded FDA indication in advanced bladder cancer pharmafile
April 19, 2017
Roche’s Genentech has revealed that its immunotherapy drug Tecentriq (atezolizumab) is now enjoying an expanded ...
How Pfizer Inc. Makes Most of Its Money foxbusiness
April 18, 2017
Pfizer is organized into two business segments. The innovative health segment develops and markets prescription drugs...
Roche's Hemophilia A Drug Positive in Second Phase III Study nasdaq
April 18, 2017
Roche Holding AG 's RHHBY unit Genentech announced positive interim results from the Phase III HAVEN 2 study ...
Antiparasitic drug repurposed for treatment of brain tumours pharmafile
April 14, 2017
Researchers from The Feinstein Institute for Medical Research's Karches Center for Oncology Research has had a ...
US clears first drug for tardive dyskinesia pharmatimes
April 14, 2017
Neurocrine Biosciences’ Ingrezza has become the first drug approved to treat the hyperkinetic movement disorder tardive dyskinesia in the US.
SMC approves anti-HIV drug PrEP pharmaceutical-technology
April 14, 2017
The Scottish Medicines Consortium (SMC) has approved the treatment known as Pre Exposure Prophylaxis (PrEP) that reduces the chances of being infected with HIV.
EMA green lights Actelion’s drug after patient deaths scare pharmafile
April 11, 2017
The EMA has ruled that the five patient deaths that occurred in February of this year were not directly related to ...
Novartis takes on dry-eye market with drug in-licensing move April 10, 2017
Novartis has announced that its eyecare-focused division Alcon has in-licensed dry-eye drug ECF843 from US firm Lubris...
US beats EU on drug review times, approvals pharmatimes
April 10, 2017
US regulators have outpaced their European counterparts both on the number of new medicines approved and length of review times between 2011 and 2015, shows a new analysis published by the New England Journal of Medicine. According to the data, the US
Novartis takes home rights to Lubris’ eye drug pharmatimes
April 10, 2017
Novartis has elected to exercise an option to in-license experimental eye drug ECF843 from US biopharma Lubris.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 49 50 Next page